Extending the continuum of care for metastatic colorectal cancer
While novel agents continue to enrich the therapeutic armamentarium in this setting, patients ask for a longer survival, but also for a better quality of life
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Colorectal cancer screening: performance of a blood-based test is promising
A study reports high sensitivity and specificity of a cell-free DNA blood-based assay compared to colonoscopy
Aspirin in colorectal cancer – has it still a place in secondary prevention?
Negative results from the ASCOT trial should not discourage researchers from investigating the drug’s potential in some molecularly distinct subgroups
Studies confirm the promise of ctDNA for MRD assessment in colorectal cancer, but limitations remain
Despite positive results from trials, the use of different assays with variable sensitivities and specificities impact their interpretation and clinical validation
Neoadjuvant nivolumab plus relatlimab shows benefit in MMR-deficient colon cancers
In the NICHE-3 study, all patients achieved a pathological response
Are we over-treating patients with locally advanced rectal cancer?
Recently presented results suggest that a subset of patients with early stage rectal cancer could skip pre-operative radiotherapy, thus raising some questions about the standard of care